НовостиBenzingaFDA Accepts Roche's Fenebrutinib NDA Under Priority Review For Relapsing And Primary Progressive MS, Backed By Phase III Data Showing 51.1%, 58.5% Relapse Reductions Vs Teriflunomide FDA Accepts Roche's Fenebrutinib NDA Under Priority Review For Relapsing And Primary Progressive MS, Backed By Phase III Data Showing 51.1%, 58.5% Relapse Reductions Vs Teriflunomide Benzinga 2026.09.30 06:43 (GMT+0) Открыть на Benzinga Другие новости